% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Winter:292541,
      author       = {R. Winter$^*$ and M. Amghar$^*$ and A. S. Wacker and G.
                      Bakos$^*$ and H. Tas$^*$ and M. Roscher$^*$ and J. M. Kelly
                      and M. Benesova-Schäfer$^*$},
      title        = {{F}uture {T}reatment {S}trategies for {C}ancer {P}atients
                      {C}ombining {T}argeted {A}lpha {T}herapy with {P}illars of
                      {C}ancer {T}reatment: {E}xternal {B}eam {R}adiation
                      {T}herapy, {C}heckpoint {I}nhibition {I}mmunotherapy,
                      {C}ytostatic {C}hemotherapy, and {B}rachytherapy.},
      journal      = {Pharmaceuticals},
      volume       = {17},
      number       = {8},
      issn         = {1424-8247},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2024-01784},
      pages        = {1031},
      year         = {2024},
      note         = {#EA:E270#LA:E270#},
      abstract     = {Cancer is one of the most complex and challenging human
                      diseases, with rising incidences and cancer-related deaths
                      despite improved diagnosis and personalized treatment
                      options. Targeted alpha therapy (TαT) offers an exciting
                      strategy emerging for cancer treatment which has proven
                      effective even in patients with advanced metastatic disease
                      that has become resistant to other treatments. Yet, in many
                      cases, more sophisticated strategies are needed to stall
                      disease progression and overcome resistance to TαT. The
                      combination of two or more therapies which have historically
                      been used as stand-alone treatments is an approach that has
                      been pursued in recent years. This review aims to provide an
                      overview on TαT and the four main pillars of therapeutic
                      strategies in cancer management, namely external beam
                      radiation therapy (EBRT), immunotherapy with checkpoint
                      inhibitors (ICI), cytostatic chemotherapy (CCT), and
                      brachytherapy (BT), and to discuss their potential use in
                      combination with TαT. A brief description of each therapy
                      is followed by a review of known biological aspects and
                      state-of-the-art treatment practices. The emphasis, however,
                      is given to the motivation for combination with TαT as well
                      as the pre-clinical and clinical studies conducted to date.},
      subtyp        = {Review Article},
      keywords     = {alpha-emitters (Other) / brachytherapy (Other) / checkpoint
                      inhibitors (Other) / combination therapy (Other) /
                      cytostatic chemotherapy (Other) / external beam radiation
                      therapy (Other) / immunotherapy (Other) / pre-clinical and
                      clinical studies (Other) / targeted alpha therapy (Other) /
                      targeted radionuclide therapy (Other)},
      cin          = {E270 / W630},
      ddc          = {610},
      cid          = {I:(DE-He78)E270-20160331 / I:(DE-He78)W630-20160331},
      pnm          = {315 - Bildgebung und Radioonkologie (POF4-315)},
      pid          = {G:(DE-HGF)POF4-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39204136},
      pmc          = {pmc:PMC11359268},
      doi          = {10.3390/ph17081031},
      url          = {https://inrepo02.dkfz.de/record/292541},
}